P030052/S030: UroVysion Bladder Cancer Kit
FDA’s recorded scope: implementation of a secondary packaging process
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Abbott Molecular. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Feb 18, 2026 to Feb 18, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
The largest PMA family in this collection is P030052, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 1300 E Touhy Ave., Des Plaines, IL, 60018. Recorded on P030052/S030, decision dated Feb 18, 2026.
FDA’s recorded scope: implementation of a secondary packaging process
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.